DT-168
DTX-168-201
Phase 2 small_molecule active
Quick answer
DT-168 for Fuchs Endothelial Corneal Dystrophy is a Phase 2 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lxo Ireland Designated Activity Company
- Indication
- Fuchs Endothelial Corneal Dystrophy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active